T Cell Metabolism in Cancer Immunotherapy: A Research Guide

Introduction

T cells are central to the immune system's ability to detect and eliminate cancer. Over the past decade, advances in immunotherapy, particularly chimeric antigen receptor T cell (CAR-T) therapy and tumor-infiltrating lymphocyte (TIL) therapy, have demonstrated that harnessing T cells can produce remarkable clinical responses in certain cancers. CAR-T cells are genetically engineered ex vivo to express a tumor-targeting receptor, while TIL therapies expand naturally occurring tumor-reactive lymphocytes for reinfusion; these distinct manufacturing approaches carry different metabolic implications discussed throughout this guide.

The effectiveness of T cell–based therapies is strongly influenced by the metabolic state of the cells. T cells must generate sufficient energy and biosynthetic intermediates to proliferate, differentiate, and sustain cytotoxic activity. These metabolic processes become particularly important in the tumor microenvironment, where immune cells encounter conditions such as hypoxia, nutrient depletion, and metabolic competition from tumor cells (Buck et al., 2017; Scharping & Delgoffe, 2016).

The field of immunometabolism has revealed that metabolic pathways regulate T cell activation, differentiation, persistence, and exhaustion. Understanding how these pathways function and how they can be manipulated during cell therapy development has become an important focus of cancer immunotherapy research (Buck et al., 2017).

Metabolic Programs of T Cells

T cells undergo distinct metabolic transitions as they move through different functional states. These metabolic programs support the energetic and biosynthetic requirements associated with immune responses.

Naïve T Cells

Naïve T cells circulate through lymphoid tissues in a relatively quiescent state. In this state, they rely primarily on oxidative phosphorylation (OXPHOS) to produce ATP (Pearce et al., 2013). This metabolic program supports long-term survival and maintenance without requiring high levels of biosynthesis.

Oxidative metabolism is efficient for ATP production and supports the longevity of naïve T cells, which may remain in circulation for extended periods prior to antigen exposure (Pearce et al., 2013).

Activated Effector T Cells

Following antigen recognition, T cells rapidly undergo metabolic reprogramming. Activated T cells switch to aerobic glycolysis, a metabolic pathway that converts glucose to lactate even in the presence of oxygen. This phenomenon, sometimes called the Warburg effect by analogy with the aerobic glycolysis first characterized in cancer cells, is broadly observed in rapidly proliferating cells, including activated immune cells (Buck et al., 2017).

Although glycolysis generates less ATP per molecule of glucose than oxidative phosphorylation, it enables rapid production of metabolic intermediates required for:

• nucleotide synthesis

• amino acid production

• lipid biosynthesis

• rapid cellular proliferation

This metabolic shift supports the rapid expansion and effector functions of activated T cells during immune responses (Pearce et al., 2013; Buck et al., 2017).

Key signaling pathways involved in driving this glycolytic transition include:

• mTOR signaling

• MYC activation

• HIF-1α stabilization (primarily under hypoxic conditions, contributing to sustained glycolysis in low-oxygen environments such as the tumor microenvironment)

mTOR and MYC are considered the dominant early drivers of the activation-induced glycolytic switch in normoxia, while HIF-1α reinforces and sustains glycolytic metabolism particularly under hypoxia (Buck et al., 2017; Palazon et al., 2014).

Memory T Cells

After an immune response resolves, a subset of T cells differentiates into memory T cells. These cells possess enhanced longevity and the ability to mount rapid responses upon re-encountering antigen.

During the contraction phase, memory T cell precursors undergo a metabolic transition that transiently involves de novo fatty acid synthesis before settling into a reliance on fatty acid oxidation (FAO) and oxidative phosphorylation for long-term energy needs. This transition is supported by increased mitochondrial biogenesis and metabolic flexibility—the capacity to utilize multiple fuel sources depending on availability (Pearce et al., 2013).

Metabolic flexibility refers to a cell's ability to switch between fuel sources (e.g., glucose, fatty acids, glutamine) in response to environmental conditions. This feature is highly desirable for therapeutic T cells used in adoptive cell therapies, as it supports persistence across variable in vivo environments.

Metabolic Stress in the Tumor Microenvironment

Tumors create a metabolically challenging environment for immune cells. As tumors grow, they consume large quantities of nutrients and oxygen, leading to several metabolic stressors that can impair immune cell function.

Hypoxia

Many tumors contain regions of low oxygen tension, or hypoxia, due to abnormal vascularization and rapid cell proliferation. Oxygen levels within tumors can fall well below those found in normal tissues, sometimes reaching less than 1–2% O₂ (Vaupel & Mayer, 2007; Carreau et al., 2011).

Hypoxia activates transcription factors such as HIF-1α, which regulate cellular adaptation to low oxygen conditions and influence immune cell metabolism (Palazon et al., 2014).

Nutrient Competition

Cancer cells often consume large quantities of glucose, glutamine, and other nutrients needed for rapid proliferation. This creates competition between tumor cells and immune cells for metabolic resources (Scharping & Delgoffe, 2016).

Reduced nutrient availability can impair T cell activation and reduce effector functions such as cytokine production and cytotoxic activity (Buck et al., 2017).

Lactate Accumulation

Tumor cells frequently rely on glycolysis, producing large amounts of lactate. The resulting acidic microenvironment can suppress T cell activity and inhibit immune responses.

High lactate concentrations have been shown to impair T cell proliferation and interfere with cytokine signaling (Scharping & Delgoffe, 2016).

T Cell Exhaustion and Metabolic Dysfunction

One major challenge in cancer immunotherapy is T cell exhaustion, a dysfunctional state characterized by reduced proliferation, diminished cytokine production, and increased expression of inhibitory receptors such as PD-1.

Metabolic dysfunction plays a key role in the development of exhaustion phenotypes. Within tumors, T cells often exhibit:

• impaired mitochondrial function

• reduced oxidative metabolism

• altered nutrient uptake

These metabolic defects can limit the ability of T cells to sustain antitumor responses (Scharping & Delgoffe, 2016).

Improving the metabolic fitness of therapeutic T cells has therefore become an important goal in the development of next-generation immunotherapies.

Metabolic Engineering Strategies in Immunotherapy

Researchers are exploring several approaches to improve T cell metabolism and enhance therapeutic outcomes. These strategies differ somewhat between CAR-T and TIL manufacturing platforms, though the underlying metabolic goals overlap.

Genetic Engineering

Genetic modifications can be used to alter metabolic pathways in engineered immune cells. Modifying regulators of metabolism may help T cells maintain function within the hostile tumor microenvironment (Buck et al., 2017).

Cytokine Signaling

Cytokines used during T cell expansion can influence metabolic programming and differentiation state. Certain cytokine combinations promote phenotypes associated with long-term persistence (Pearce et al., 2013).

Environmental Conditioning

Culture conditions during cell expansion, including oxygen levels, nutrient composition, and environmental stress signals, may influence metabolic programs and functional characteristics of T cells.

These approaches aim to produce immune cells better equipped to function within the challenging conditions present in tumors (Scharping & Delgoffe, 2016).

Implications for Cell Therapy Development

The metabolic state of T cells is shaped not only by genetic factors but also by environmental conditions during cell culture and manufacturing.

Traditional cell culture systems typically operate under atmospheric oxygen levels (~21% O₂). However, immune cells in tissues and tumors often experience substantially lower oxygen concentrations (Carreau et al., 2011).

Understanding how environmental variables such as oxygen levels influence immune cell metabolism may help researchers design experimental systems that more accurately model in vivo conditions.

Improved control over cell culture environments may enable researchers to study how metabolic conditioning strategies influence immune cell function during immunotherapy development.

Key Research Questions

The study of T cell metabolism continues to raise important questions for the future of cancer immunotherapy:

• How do metabolic pathways influence T cell persistence after infusion?

• Can metabolic conditioning improve therapeutic outcomes in solid tumors?

• How do environmental conditions during cell manufacturing affect immune cell fitness?

• What strategies can overcome metabolic suppression in the tumor microenvironment?

• How do the distinct manufacturing processes for CAR-T and TIL therapies differentially shape the metabolic fitness of the final cell product?

Answering these questions will help guide the development of next-generation cell therapies capable of overcoming the challenges posed by the tumor microenvironment.

Conclusion

T cell metabolism has emerged as a critical factor in determining the effectiveness of cancer immunotherapies. The metabolic programs that regulate T cell activation, differentiation, and persistence are tightly linked to the environmental conditions encountered by immune cells in tumors.

As the field of immunometabolism advances, researchers are increasingly focused on strategies that improve the metabolic fitness of therapeutic immune cells. These efforts may ultimately lead to more durable and effective cell-based treatments for cancer.

Frequently Asked Questions

What is T cell metabolism?

T cell metabolism refers to the biochemical pathways that immune cells use to generate energy and biosynthetic intermediates required for proliferation, differentiation, and effector function. Different T cell states—including naïve, effector, and memory cells—use distinct metabolic programs such as oxidative phosphorylation, glycolysis, and fatty acid oxidation to support their functions (Pearce et al., 2013; Buck et al., 2017).

Why is metabolism important for cancer immunotherapy?

The metabolic state of T cells strongly influences their ability to persist and function in tumors. Within the tumor microenvironment, immune cells encounter conditions such as hypoxia, nutrient competition, and metabolic stress that can impair their activity. Improving the metabolic fitness of therapeutic T cells is therefore an important strategy in developing more effective cancer immunotherapies (Scharping & Delgoffe, 2021).

How does the tumor microenvironment affect T cells?

Tumors create a challenging metabolic environment characterized by low oxygen levels, limited nutrients, and accumulation of metabolic byproducts such as lactate. These factors can alter T cell metabolism, suppress immune activity, and contribute to T cell exhaustion, limiting the effectiveness of antitumor immune responses (Vaupel & Mayer, 2007; Scharping & Delgoffe, 2021).

What metabolic pathways do activated T cells use?

Activated T cells primarily rely on aerobic glycolysis to support rapid proliferation and effector functions. This metabolic shift allows cells to generate the biosynthetic intermediates required for cell growth and immune responses, even though it produces less ATP per molecule of glucose than oxidative phosphorylation (Buck et al., 2017).

Can metabolic conditioning improve cell therapy outcomes?

Researchers are increasingly exploring ways to manipulate metabolic pathways during immune cell expansion and engineering. Strategies such as genetic modifications, cytokine signaling modulation, and environmental conditioning during cell culture may help produce therapeutic T cells that are better adapted to the metabolic stresses present in tumors.

References

Buck MD, O’Sullivan D, Pearce EL. (2017). Metabolic instruction of immunity. Cell, 169(4), 570–586. https://doi.org/10.1016/j.cell.2017.04.004

Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. (2011). Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. Journal of Cellular and Molecular Medicine, 15(6), 1239–1253.

Palazon A, Goldrath AW, Nizet V, Johnson RS. (2014). HIF transcription factors, inflammation, and immunity. Immunity, 41(4), 518–528.

Pearce EL, Poffenberger MC, Chang CH, Jones RG. (2013). Fueling immunity: Insights into metabolism and lymphocyte function. Science, 342(6155), 1242454.

Scharping NE, Delgoffe GM. (2016). Tumor microenvironment metabolism: A new checkpoint for anti-tumor immunity. Vaccines, 4(4), 46.

Vaupel P, Mayer A. (2007). Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Reviews, 26(2), 225–239.

Explore AVATAR Bioprocessing

Advances in immunometabolism are driving new approaches to cell therapy manufacturing. Learn how AVATAR™ systems enable precise environmental control to support T cell potency and persistence.

Explore AVATAR Technology →